Skip to main
BOLD
BOLD logo

BOLD Stock Forecast & Price Target

BOLD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Boundless Bio Inc., a clinical-stage oncology company, is positioned favorably due to its innovative approach to targeting extrachromosomal DNA (ecDNA), which addresses a significant unmet need in oncogene-amplified tumors. The development of its ecDTx, BBI-355, as a selective inhibitor of checkpoint kinase 1 (CHK1) could enhance therapeutic efficacy while mitigating toxicity, emphasizing the potential for improved patient outcomes. Moreover, the company's previous work in the kinesin targeting space supports a positive evolution toward precision therapies, indicating that successful advancements could yield substantial upside beyond current valuations.

Bears say

Boundless Bio Inc. faces significant challenges related to the clinical development of its lead candidate, BBI-355, which has encountered negative clinical data and concerns over its therapeutic window. The company is also at risk of delays in obtaining regulatory approval and may experience setbacks with its pipeline programs, leading to uncertainty in future growth. Additionally, slower-than-anticipated commercial uptake of BBI-355 and potential dilution risks raise further concerns about the sustainability of its financial position.

BOLD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boundless Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boundless Bio Inc (BOLD) Forecast

Analysts have given BOLD a Buy based on their latest research and market trends.

According to 2 analysts, BOLD has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boundless Bio Inc (BOLD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.